Cargando…

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

Background. Randomized studies have shown different magnitude of bevacizumab benefit in the treatment of advanced breast cancer. Regulatory agencies have modified bevacizumab treatment indications across different regions. In this study, we perform a meta-analysis of phase III studies aiming to inte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossari, José R., Metzger-Filho, Otto, Paesmans, Marianne, Saini, Kamal S., Gennari, Alessandra, de Azambuja, Evandro, Piccart-Gebhart, Martine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447373/ https://www.ncbi.nlm.nih.gov/pubmed/23008712 http://dx.doi.org/10.1155/2012/417673

Ejemplares similares

Targeted therapies in breast cancer: are heart and vessels also being targeted?
por: Criscitiello, Carmen, et al.
Publicado: (2012)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
por: Maurer, Christian, et al.
Publicado: (2018)

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25
por: Pinto, Ana Catarina, et al.
Publicado: (2014)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
por: Snoj, Natasa, et al.
Publicado: (2009)

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
por: de Azambuja, E, et al.
Publicado: (2007)

New generation of breast cancer clinical trials implementing molecular profiling
por: Zardavas, Dimitrios, et al.
Publicado: (2016)

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
por: Caparica, Rafael, et al.
Publicado: (2019)

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA
por: Ades, Felipe, et al.
Publicado: (2017)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
por: Fernández-Cuesta, Lynnette, et al.
Publicado: (2012)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2021)

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2022)

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
por: Lambertini, Matteo, et al.
Publicado: (2020)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Treatment of early-stage HER2+ breast cancer—an evolving field
por: Ferreira, Arlindo R, et al.
Publicado: (2015)

Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer
por: Metzger-Filho, Otto, et al.
Publicado: (2013)

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Clinical Audit: Time for a Reappraisal?
por: Rigge, Marianne
Publicado: (1996)

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2016)

Targeting immune checkpoints in breast cancer: an update of early results
por: Solinas, Cinzia, et al.
Publicado: (2017)

The current use and attitudes towards tumor genome sequencing in breast cancer
por: Gingras, I., et al.
Publicado: (2016)

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
por: Brandão, Mariana, et al.
Publicado: (2020)

Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report
por: Mhamdi, Hasnae Alaoui, et al.
Publicado: (2017)

A Reappraisal of How to Build Modular, Reusable Models of Biological Systems
por: Neal, Maxwell L., et al.
Publicado: (2014)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study(†)
por: Iwamoto, S., et al.
Publicado: (2015)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
por: Hendlisz, Alain, et al.
Publicado: (2013)

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies
por: Saini, Kamal S., et al.
Publicado: (2020)

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
por: Reck, M., et al.
Publicado: (2010)

Oxazepam and cognitive reappraisal: A randomised experiment
por: Nilsonne, Gustav, et al.
Publicado: (2021)

Immunotherapy in breast cancer: an overview of current strategies and perspectives
por: Debien, Véronique, et al.
Publicado: (2023)

Neural bases of reappraisal regulatory effect on negative emotion in high reappraisers☆
por: Zhang, Wencai, et al.
Publicado: (2012)

Low CD10 mRNA Expression Identifies High-Risk Ductal Carcinoma In Situ (DCIS)
por: Toussaint, Jérôme, et al.
Publicado: (2010)

Challenges in launching multinational oncology clinical trials in India
por: Saini, Kamal S., et al.
Publicado: (2013)

Neurogenic Appendicitis: A Reappraisal of the Clinicopathological Features and Pathogenesis
por: Hussein, Mahmoud Rezk Abdelwahed, et al.
Publicado: (2022)

Reappraising the dimensional structure of the PTSD Checklist: lessons from the DSM-IV-based PCL-C
por: Reichenheim, Michael E., et al.
Publicado: (2017)

Reappraisals in Renaissance thought
por: Nutton, Vivian
Publicado: (1990)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_855bgjd18e3qcrd5indqf6tm36